

## Corium International Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 07-Mar-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

# Corium International Inc

## COMPANY OVERVIEW

|                                       |  |
|---------------------------------------|--|
| Company Name                          | Corium International Inc   |
| Parent Company Name                   | Corium International Inc   |
| Website                               | http://www.coriumgroup.com/  |
| Country                               | US   |
| Number of Drugs in Active Development | 7  |
| Number of Inactive Drugs              | 0  |
| Number of Patents as Owner            | 5  |
| Number of Patents as Third Party      | 0  |
| Number of Deals                       | 4  |
| Key Indications                       | Alzheimers disease,Osteoporosis,Prostate hyperplasia,Parkinsons disease,Poliovirus infection,Psychiatric disorder,Urinary dysfunction,Urinary tract disease  |
| Key Target-based Actions              | Acetylcholinesterase inhibitor,Parathyroid hormone receptor agonist,Alpha adrenoceptor antagonist,Dopamine D2 receptor agonist,Dopamine D3 receptor agonist,NMDA receptor antagonist,Parathyroid hormone ligand,Alpha 1A adrenoceptor antagonist |
| Key Technologies                      | Transdermal formulation,Patch formulation,Small molecule therapeutic,Biological therapeutic,Drug combination,Peptide,Controlled release formulation,Absorption enhancer transdermal,Formulation preservation,Sustained release formulation       |

## COMPANY PROFILE

### SUMMARY

Corium International Inc specializes in the R&D and manufacture of transdermal drug delivery platforms and products.

### FINANCIAL

In December 2014, the company revised and closed an expanded term loan facility with CRG (previously known as Capital Royalty L.P.). Under the revised term, the company would get additional \$10 million from CRG cumulating the total loan amount to \$45 million and the maturity date of the all the debt to CRG was changed from June 2017 to June 2019.

In March 2014, Corium filed a registration statement Form S-1 with the US SEC for a proposed initial public offering of common stock. At that time, the company planned to list on the NASDAQ Global Market under the ticker symbol 'CORI'. In April 2014, the company priced its initial public offering of 6,500,000 shares of common stock priced at \$8.00 each and the underwriters were granted a 30-day option to purchase up to 975,000 additional shares of common stock. At that time, the shares began trading on the NASDAQ Stock Market. By May 2014, the initial public offering was completed and the company raised \$48.5 million net proceeds through the offering.

## COMPANY FINANCIALS

### SHARE INFORMATION

|                            |              |
|----------------------------|--------------|
| Close Price (USD)          | 7.10         |
| Change (USD)               | 0.16 (2.31%) |
| Previous Close Price (USD) | 6.94         |

[Return to Table of Contents](#)



|                                      |                   |
|--------------------------------------|-------------------|
| Volume                               | 10,013            |
| 52-Week High (USD)                   | 8.49              |
| 52-Week Low (USD)                    | 4.30              |
| Date                                 | 06-Mar-2015       |
| Exchange                             | NASDAQ(COMPOSITE) |
| Current Number of Shares Outstanding | 18,070,838        |
| Current Market Capitalization        | 125,050,199       |
| EPS (Date Reported)                  | -1.15279          |

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS


| Shareholder                            | Type            | Country       | Shares held | % of shares held | Change in holding | % changes in shares held | Date        |
|--|-----------------|---------------|-------------|------------------|-------------------|--------------------------|-------------|
| Essex Woodlands Health Ventures        | Venture Capital | United States | 9,353,304   | 51.76            | 0                 | 0                        | 18-Feb-2015 |
| Vanguard Total Stock Market Index Fund | Mutual Fund     | United States | 81,050      | 0.45             | 3,050             | 0.04                     | 31-Jan-2015 |

[Return to Table of Contents](#)

|   |                               |               |        |      |        |   |             |
|---|-------------------------------|---------------|--------|------|--------|---|-------------|
| Fidelity Spartan Extended Market Index Fund           | Mutual Fund                   | United States | 21,362 | 0.12 | 0      | 0 | 31-Jan-2015 |
| Staple (Peter D)                                      | Individual Investor           | United States | 19,778 | 0.11 | 19,778 | 1 | 14-Jan-2015 |
| AXA Premier VIP Multimanager Mid Cap Growth Portfolio | Mutual Fund                   | United States | 11,125 | 0.06 | 0      | 0 | 31-Jan-2015 |
| Singh Parminder                                       | Individual Investor           | United States | 6,940  | 0.04 | 6,940  | 1 | 14-Jan-2015 |
| Breuil (Robert S)                                     | Individual Investor           | United States | 5,600  | 0.03 | 5,600  | 1 | 14-Jan-2015 |
| Guggenheim Investments                                | Investment Advisor/Hedge Fund | United States | 1,542  | 0.01 | 0      | 0 | 28-Feb-2015 |
| Wilshire Micro-Cap ETF                                | Mutual Fund                   | United States | 1,542  | 0.01 | 0      | 0 | 31-Jan-2015 |
| AXA/Lord Abbett Micro Cap Portfolio                   | Mutual Fund                   | United States | 969    | 0.01 | 0      | 0 | 31-Jan-2015 |

## FINANCIAL PERFORMANCE

### Sales and Income



[Return to Table of Contents](#)



|                                 | 2012   | 2014    | 2013    |  |  |
|---------------------------------|--------|---------|---------|--|--|
| <b>Sales (USD M)</b>            | 42.86  | 42.44   | 50.27   |  |  |
| <b>Operating Income (USD M)</b> | -0.867 | -10.162 | 1.024   |  |  |
| <b>Net Income (USD M)</b>       | -5.443 | -9.912  | -13.877 |  |  |

#### Quarterly earnings update

| Period  | Sales (USD M) | Operating Income (USD M) | Net Income (USD M) |
|---------|---------------|--------------------------|--------------------|
| 2015 Q1 | 9.766         | -5.083                   | -6.759             |
| 2014 Q4 | 11.072        | -4.816                   | -6.367             |
| 2014 Q3 | 10.183        | -3.421                   | -4.981             |
| 2014 Q2 | 10.717        | -0.826                   | 3.534              |
| 2014 Q1 | 10.468        | -1.099                   | -2.098             |
| 2013 Q4 | 12.544        | 0.131                    | -1.282             |
| 2013 Q3 | 12.566        | 0.725                    | -9.163             |
| 2013 Q2 | 12.536        | -0.126                   | -1.999             |
| 2013 Q1 | 12.624        | 0.294                    | -1.433             |

#### BALANCE SHEET

##### Assets (USD M)

|  | 2012   | 2013   | 2014   |  |  |
|--|--------|--------|--------|--|--|
| <b>Cash &amp; Short Term Investments</b>   | 12.245 | 13.581 | 36.395 |  |  |
| <b>Inventories - Total</b>                 | 4.369  | 4.508  | 2.592  |  |  |
| <b>Current Assets - Total</b>              | 22.482 | 23.751 | 45.832 |  |  |
| <b>Property, Plant And Equipment - Net</b> | 7.024  | 12.622 | 12.658 |  |  |
| <b>Other Assets - Total</b>                | 7.696  | 7.549  | 7.254  |  |  |
| <b>Total Assets</b>                        | 37.202 | 44.022 | 65.744 |  |  |

[Return to Table of Contents](#)

## Liabilities (USD M)

|   | 2012   | 2013    | 2014   |  |  |
|---|--------|---------|--------|--|--|
| Accounts Payable                                    | 3.298  | 2.748   | 2.512  |  |  |
| Short Term Debt & Current Portion Of Long Term Debt | 2.728  | 5.359   | 0.867  |  |  |
| Current Liabilities - Total                         | 11.38  | 15.157  | 8.462  |  |  |
| Long Term Debt                                      | 52.631 | 61.007  | 39.046 |  |  |
| Other Liabilities                                   | 14.44  | 22.785  | 2.936  |  |  |
| Total Liabilities                                   | 83.063 | 102.637 | 53.944 |  |  |

## Stockholders Equity (USD M)

|  | 2012   | 2013   | 2014   |  |  |
|--|--------|--------|--------|--|--|
| Minority Interest                        | 0      | 0      | 0      |  |  |
| Preferred Stock                          | 57.261 | 57.261 | 0      |  |  |
| Common Stock                             | 3.226  | 3.226  | 0.018  |  |  |
| Treasury Stock                           |        |        | 0      |  |  |
| Total Liabilities & Shareholders' Equity | 37.202 | 44.022 | 65.744 |  |  |

## FORECASTS

### EPS Forecast

| Year ending | Current Forecast | 1 month ago | 3 months ago |
|-------------|------------------|-------------|--------------|
| 31-Dec-2015 | -0.87            | -1.25       | -0.87        |
| 31-Dec-2016 | -0.79            | -0.98       | -0.79        |
| 31-Dec-2017 | -0.56            | -0.73       | -0.56        |

### Other Forecasts

| Year ending | DPS | CPS  | Pretax | Sales |
|-------------|-----|------|--------|-------|
| 31-Dec-2015 |     | 1.94 | -25    | 42.44 |
| 31-Dec-2016 |     |      | -17    | 52.85 |
| 31-Dec-2017 |     |      | -12.45 | 69.67 |


[Return to Table of Contents](#)

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)




## Drugs by Indication Table

| Indication              | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Neurological disease    | 4      | 0        | 4     |
| Degeneration            | 3      | 0        | 3     |
| Andrology               | 1      | 0        | 1     |
| Inflammatory disease    | 1      | 0        | 1     |
| Genitourinary disease   | 1      | 0        | 1     |
| Endocrine disease       | 1      | 0        | 1     |
| Psychiatric disorder    | 1      | 0        | 1     |
| Musculoskeletal disease | 1      | 0        | 1     |
| Growth disorder         | 1      | 0        | 1     |
| Infectious disease      | 1      | 0        | 1     |

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 1 Clinical   | 1               |
| Discovery          | 5               |
| Suspended          | 1               |

## DEALS

| Deal Type                                    | Principal |          | Partner |          | Total |
|--|-----------|----------|---------|----------|-------|
|  | Active    | Inactive | Active  | Inactive |       |
| Drug - Funding                               | 1         | 0        | 0       | 0        | 1     |
| Drug - Development/Commercialization License | 0         | 0        | 1       | 0        | 1     |
| Drug - Manufacturing/Supply                  | 2         | 0        | 0       | 0        | 2     |

## CLINICAL TRIALS

### Trials by Phase

| Phase   | Ongoing | All |
|---------|---------|-----|
| Phase 1 | 0       | 1   |

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

| Indication               | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease   | 1        | 0              | 1     |
| Endocrine disease        | 6        | 0              | 6     |
| Gastrointestinal disease | 2        | 0              | 2     |
| Genitourinary disease    | 1        | 0              | 1     |
| Growth disorder          | 1        | 0              | 1     |
| Degeneration             | 5        | 0              | 5     |

[Return to Table of Contents](#)



|                         |   |   |   |
|-------------------------|---|---|---|
| Andrology               | 1 | 0 | 1 |
| Psychiatric disorder    | 1 | 0 | 1 |
| Musculoskeletal disease | 5 | 0 | 5 |
| Neoplasm                | 1 | 0 | 1 |
| Metabolic disorder      | 1 | 0 | 1 |
| Neurological disease    | 3 | 0 | 3 |
| Respiratory disease     | 1 | 0 | 1 |
| Infectious disease      | 3 | 0 | 3 |
| Injury                  | 1 | 0 | 1 |
| Inflammatory disease    | 2 | 0 | 2 |
| Ulcer                   | 1 | 0 | 1 |

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### teriparatide (transdermal, MicroCor, osteoporosis), Corium International

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | teriparatide (transdermal, MicroCor, osteoporosis), Corium International    |
| <b>Key Synonyms</b>         | teriparatide, MicroCor PTH(1-34)  |
| <b>Originator Company</b>   | Corium International Inc  |
| <b>Active Companies</b>     | Corium International Inc  |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Phase 1 Clinical  |
| <b>Active Indications</b>   | Osteoporosis  |
| <b>Target-based Actions</b> | Parathyroid hormone receptor agonist, Parathyroid hormone ligand            |
| <b>Other Actions</b>        | Osteoblast stimulator, Bone synthesis stimulator                            |
| <b>Technologies</b>         | Transdermal formulation, Patch formulation, Biological therapeutic, Peptide |
| <b>Last Change Date</b>     | 17-Feb-2015   |

### aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium |
| <b>Key Synonyms</b>         | aripiprazole  |
| <b>Originator Company</b>   | Transdermal Research Pharm Laboratories LLC   |
| <b>Active Companies</b>     | Aequus Pharmaceuticals Inc, Corium International Inc                                  |
| <b>Inactive Companies</b>   | Transdermal Research Pharm Laboratories LLC   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | Psychiatric disorder  |
| <b>Target-based Actions</b> | 5-HT 2a receptor antagonist   |
| <b>Other Actions</b>        | Antipsychotic, Dopamine D2 receptor partial agonist, 5-HT 1a receptor partial agonist |
| <b>Technologies</b>         | Transdermal formulation, Patch formulation, Small molecule therapeutic                |
| <b>Last Change Date</b>     | 24-Nov-2014   |

[Return to Table of Contents](#)



### polio vaccine (transdermal), Corium

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | polio vaccine (transdermal), Corium                                |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Corium International Inc   |
| <b>Active Companies</b>     | Corium International Inc   |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Poliovirus infection   |
| <b>Target-based Actions</b> |  |
| <b>Other Actions</b>        | Vaccine, Anti-inflammatory   |
| <b>Technologies</b>         | Transdermal formulation, Patch formulation, Biological therapeutic |
| <b>Last Change Date</b>     | 19-Nov-2014  |

### donepezil (transdermal patch, Alzheimers disease), Corium

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | donepezil (transdermal patch, Alzheimers disease), Corium              |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Corium International Inc   |
| <b>Active Companies</b>     | Corium International Inc   |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Alzheimers disease   |
| <b>Target-based Actions</b> | Acetylcholinesterase inhibitor   |
| <b>Other Actions</b>        | Neuroprotectant, Nootropic agent                                       |
| <b>Technologies</b>         | Transdermal formulation, Patch formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 25-Nov-2014  |

[Return to Table of Contents](#)



### donepezil + memantine (transdermal patch, Alzheimers disease), Corium

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | donepezil + memantine (transdermal patch, Alzheimers disease), Corium                    |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Corium International Inc   |
| <b>Active Companies</b>     | Corium International Inc   |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Alzheimers disease   |
| <b>Target-based Actions</b> | Acetylcholinesterase inhibitor, NMDA receptor antagonist                                 |
| <b>Other Actions</b>        | Neuroprotectant, Nootropic agent   |
| <b>Technologies</b>         | Drug combination, Transdermal formulation, Patch formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 17-Feb-2015  |

### ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium                 |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Corium International Inc   |
| <b>Active Companies</b>     | Corium International Inc   |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Parkinsons disease   |
| <b>Target-based Actions</b> | Dopamine D2 receptor agonist, Dopamine D3 receptor agonist                               |
| <b>Other Actions</b>        | Antiparkinsonian   |
| <b>Technologies</b>         | Drug combination, Transdermal formulation, Patch formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 18-Feb-2015  |

[Return to Table of Contents](#)



### tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium                                 |
| <b>Key Synonyms</b>         | tamsulosin   |
| <b>Originator Company</b>   | Corium International Inc   |
| <b>Active Companies</b>     | Corium International Inc   |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Prostate hyperplasia   |
| <b>Target-based Actions</b> | Alpha adrenoceptor antagonist  |
| <b>Other Actions</b>        |  |
| <b>Technologies</b>         | Transdermal formulation, Patch formulation, Controlled release formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 16-Feb-2015  |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

